Clinical Trial

Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy

Study acronym: ReActiF-ICE
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 25, 2025 (before its estimated March 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Evaluation of a novel therapy approach for severe sepsis patients. Subjects randomized into the treatment arm receive treatment with an immune cell perfusion system on top of standard care. This may contribute to the improvement of the impaired organ function of septic shock patients by assisting the impaired immune system (immune competence enhancement = ARTICE)
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2022-06-28; most recent amendment 2025-05-21.
Status change: Not Yet Recruiting → Recruiting 2022-07-26
Trial Details
NCT Number NCT05442710
Lead Sponsor Artcline GmbH
Collaborators: Zentrum für Klinische Studien Jena, RQM+
Conditions Sepsis, Severe
Enrollment 142 participants
Start Date 2022-07-24
Primary Completion 2026-03-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-25